Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KOD |
---|---|---|
09:32 ET | 3782 | 3.655 |
09:34 ET | 2323 | 3.71 |
09:36 ET | 1400 | 3.7405 |
09:39 ET | 1000 | 3.7601 |
09:41 ET | 1000 | 3.75 |
09:43 ET | 300 | 3.76 |
09:45 ET | 200 | 3.735 |
09:48 ET | 700 | 3.76 |
09:50 ET | 500 | 3.76 |
09:52 ET | 1200 | 3.74 |
09:54 ET | 100 | 3.73 |
10:01 ET | 500 | 3.75 |
10:03 ET | 600 | 3.76 |
10:06 ET | 1900 | 3.78 |
10:08 ET | 600 | 3.8 |
10:10 ET | 500 | 3.8 |
10:12 ET | 900 | 3.78 |
10:14 ET | 1801 | 3.76 |
10:15 ET | 1100 | 3.7811 |
10:17 ET | 300 | 3.78 |
10:19 ET | 100 | 3.76 |
10:28 ET | 341 | 3.785 |
10:30 ET | 250 | 3.79 |
10:32 ET | 1000 | 3.786 |
10:33 ET | 100 | 3.79 |
10:35 ET | 500 | 3.79 |
10:37 ET | 600 | 3.794 |
10:44 ET | 500 | 3.78 |
10:50 ET | 600 | 3.785 |
10:53 ET | 200 | 3.775 |
10:55 ET | 100 | 3.78 |
10:57 ET | 205 | 3.775 |
11:00 ET | 200 | 3.78 |
11:04 ET | 100 | 3.79 |
11:06 ET | 100 | 3.79 |
11:08 ET | 200 | 3.79 |
11:09 ET | 400 | 3.795 |
11:11 ET | 100 | 3.79 |
11:20 ET | 100 | 3.8 |
11:22 ET | 100 | 3.8 |
11:24 ET | 2991 | 3.805 |
11:26 ET | 100 | 3.82 |
11:27 ET | 250 | 3.8121 |
11:29 ET | 2098 | 3.815 |
11:31 ET | 3512 | 3.8401 |
11:33 ET | 1000 | 3.85 |
11:36 ET | 1009 | 3.81 |
11:38 ET | 100 | 3.81 |
11:42 ET | 4700 | 3.77 |
11:47 ET | 7402 | 3.81 |
11:51 ET | 300 | 3.81 |
11:54 ET | 100 | 3.82 |
11:56 ET | 400 | 3.83 |
11:58 ET | 700 | 3.84 |
12:00 ET | 138 | 3.83 |
12:02 ET | 467 | 3.85 |
12:03 ET | 600 | 3.85 |
12:05 ET | 5960 | 3.8 |
12:07 ET | 200 | 3.8004 |
12:12 ET | 200 | 3.81 |
12:16 ET | 100 | 3.82 |
12:18 ET | 100 | 3.82 |
12:21 ET | 1300 | 3.84 |
12:23 ET | 100 | 3.84 |
12:25 ET | 300 | 3.84 |
12:27 ET | 400 | 3.84 |
12:30 ET | 119 | 3.83 |
12:32 ET | 299 | 3.8315 |
12:34 ET | 1800 | 3.835 |
12:39 ET | 112 | 3.835 |
12:41 ET | 1200 | 3.85 |
12:48 ET | 100 | 3.86 |
12:50 ET | 229 | 3.8624 |
12:52 ET | 100 | 3.87 |
12:54 ET | 350 | 3.87 |
12:56 ET | 100 | 3.87 |
12:57 ET | 1400 | 3.84 |
12:59 ET | 903 | 3.85 |
01:03 ET | 1597 | 3.84 |
01:12 ET | 2897 | 3.85 |
01:15 ET | 200 | 3.85 |
01:17 ET | 100 | 3.855 |
01:19 ET | 524 | 3.855 |
01:21 ET | 600 | 3.86 |
01:24 ET | 412 | 3.865 |
01:26 ET | 300 | 3.87 |
01:28 ET | 1164 | 3.85 |
01:33 ET | 100 | 3.8466 |
01:35 ET | 2900 | 3.85 |
01:42 ET | 367 | 3.84 |
01:44 ET | 500 | 3.84 |
01:46 ET | 2500 | 3.81 |
01:48 ET | 100 | 3.81 |
01:51 ET | 200 | 3.81 |
01:53 ET | 31294 | 3.8 |
01:55 ET | 100 | 3.8 |
01:57 ET | 2100 | 3.81 |
02:02 ET | 100 | 3.83 |
02:04 ET | 300 | 3.83 |
02:06 ET | 3696 | 3.82 |
02:08 ET | 1872 | 3.82 |
02:09 ET | 2000 | 3.8199 |
02:11 ET | 1600 | 3.8251 |
02:13 ET | 1200 | 3.8297 |
02:15 ET | 1100 | 3.835 |
02:18 ET | 2285 | 3.85 |
02:20 ET | 604 | 3.86 |
02:22 ET | 300 | 3.86 |
02:24 ET | 200 | 3.86 |
02:26 ET | 200 | 3.86 |
02:27 ET | 250 | 3.8519 |
02:29 ET | 200 | 3.86 |
02:31 ET | 200 | 3.86 |
02:36 ET | 12465 | 3.875 |
02:38 ET | 868 | 3.875 |
02:40 ET | 2289 | 3.84 |
02:45 ET | 1500 | 3.845 |
02:49 ET | 100 | 3.845 |
02:54 ET | 1469 | 3.86 |
02:56 ET | 649 | 3.86 |
02:58 ET | 1300 | 3.87 |
03:00 ET | 5980 | 3.835 |
03:02 ET | 100 | 3.84 |
03:03 ET | 623 | 3.84 |
03:07 ET | 3597 | 3.86 |
03:09 ET | 200 | 3.86 |
03:12 ET | 100 | 3.86 |
03:14 ET | 200 | 3.86 |
03:16 ET | 3836 | 3.85 |
03:18 ET | 1224 | 3.86 |
03:20 ET | 100 | 3.87 |
03:21 ET | 200 | 3.87 |
03:23 ET | 1225 | 3.86 |
03:25 ET | 100 | 3.85 |
03:27 ET | 1300 | 3.85 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kodiak Sciences Inc | 189.7M | -0.8x | --- |
Boundless Bio Inc | 191.0M | -4.2x | --- |
Galectin Therapeutics Inc | 187.6M | -4.0x | --- |
Trevi Therapeutics Inc | 192.3M | -8.1x | --- |
Atossa Therapeutics Inc | 186.7M | -6.2x | --- |
INmune Bio Inc | 198.0M | -5.8x | --- |
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $189.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.46 |
EPS | $-4.97 |
Book Value | $5.06 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.